StockData
Aldeyra Therapeutics, Inc. logo

Aldeyra Therapeutics, Inc. (ALDX) company profile

ALDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.69+0.02 (+3.63%)

Close on Nov 17, 2026Market cap $41.86MP/E –Yield –

About Aldeyra Therapeutics

Pharmaceutical Preparations, SIC 2834

Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing therapies for immune-mediated diseases. Its approach centers on modulating protein systems through small molecules designed to bind, degrade, and deplete reactive aldehyde species (RASP), targeting multiple inflammatory pathways simultaneously. The company’s pipeline includes late-stage investigational candidates such as reproxalap, an ophthalmic solution evaluated for dry eye disease and allergic conjunctivitis, and ADX-2191, an intravitreal methotrexate formulation for primary vitreoretinal lymphoma and retinitis pigmentosa. In addition, it develops product candidates like ADX-248 and ADX-246 for systemic, dermatologic, and retinal conditions.

The company operates in the United States and has an option agreement with AbbVie to collaborate on the development and commercialization of reproxalap. Aldeyra conducts preclinical research, animal studies, and clinical trials for its therapeutic candidates. It maintains its principal executive offices in Lexington, Massachusetts.

Summary of the business section of Aldeyra Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Aldeyra Therapeutics, Inc.
Headquarters
Concord, MA
Address
23 Bradford Street, Suite 1 01742
Phone
(781) 761-4904
Employees
8, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
BDO USA, P.C., Boston, Massachusetts

Stock & identifiers

Ticker
ALDX
Exchange
Nasdaq
IPO date
May 2, 2014
Shares outstanding
60M, Aug 4, 2026
Public float
$231.90M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1341235
CUSIP
01438T106
ISIN
US01438T1060
FIGI
BBG0029H8ZF6
Share class FIGI
BBG0029H8ZG5
LEI
529900HGKY864E4Y9014
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Todd C. BradyPresident and CEO, Director1,721,298
Michael AlfieriPrincipal Financial Officer17,500
Stephen MachathaChief Development Officer222,010
Darlene M. Deptula-HicksDirector7,500
Richard DouglasDirector395,000
William D. ClarkDirector–
Ben BronsteinDirector28,248
Gary M. PhillipsDirector14,812
Neal WalkerDirector15,854
Nancy Miller-RichDirector922
Martin Joseph JoyceDirector23,967

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$4.70M$4.29M$848.17K$74–
FY2024$3.93M$6.05M$1.01M$72–
FY2023$3.68M-$1.22M$1.28M$50–
FY2022$2.86M$10.61M$2.02M$174–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Todd C. Brady, M.D., Ph.D.
President and Chief Executive Officer
$700.00K$3.80M$189.00K$14.00K$4.70M+20%
Stephen G. Machatha, Ph.D.
Chief Development Officer
$400.00K$950.34K–$101.80K$1.45M-14%
Michael Alfieri
Principal Financial Officer and Principal Accounting Officer
–––$243.99K$245.96K+120%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 2, 2014
Offer price
$8.00
Securities offered
1,500,000
Gross proceeds
$12.00M
Exchange
Nasdaq
First trading day
May 2, 2014
First-day close
$7.20-10.0%
Lock-up ends (est.)
Oct 29, 2014

“Per Share Total Public offering price $ 8.00 $ 12,000,000 Underwriting discount and commissions (1) $ 0.56 $ 840,000 Offering proceeds to us before expenses $ 7.44 $ 11,160,000 (1) Does not include a non-accountable expense allowance equal to 1% of the gross proceeds of this offering payable to Aegis Capital Corp.,”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 8 full-time employees and had engaged a number of consultants.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jan 29, 2019Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 2, 2014IPOInitial public offering priced (424B4 prospectus)
Mar 4, 2014ListingRegistration of securities on an exchange (Form 8-A)
Mar 4, 2014Name changeName changed from Aldexa Therapeutics, Inc. to Aldeyra Therapeutics, Inc.
Aug 1, 2008Name changeName changed from Neuron Systems Inc to Aldexa Therapeutics, Inc.

See a number that looks wrong?